Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: a prospective study in China

AIM To optimize the efficacy of noninvasive evaluations in monitoring the endoscopic activity of inflammatory bowel disease(IBD).METHODS Fecal calprotectin(FC), clinical activity index(CDAI or CAI), C-reactive protein(CRP), erythrocyte sedimentation rate(ESR), and procalcitonin(PCT) were measured fo...

Full description

Saved in:
Bibliographic Details
Published inWorld journal of gastroenterology : WJG Vol. 23; no. 46; pp. 8235 - 8247
Main Authors Chen, Jin-Min, Liu, Tao, Gao, Shan, Tong, Xu-Dong, Deng, Fei-Hong, Nie, Biao
Format Journal Article
LanguageEnglish
Published United States Baishideng Publishing Group Inc 14.12.2017
Subjects
Online AccessGet full text

Cover

Loading…
Abstract AIM To optimize the efficacy of noninvasive evaluations in monitoring the endoscopic activity of inflammatory bowel disease(IBD).METHODS Fecal calprotectin(FC), clinical activity index(CDAI or CAI), C-reactive protein(CRP), erythrocyte sedimentation rate(ESR), and procalcitonin(PCT) were measured for 136 IBD patients. Also, FC was measured in 25 irritable bowel syndrome(IBS) patients that served as controls. Then, endoscopic activity was determined by other two endoscopists for colonic or ileo-colonic Crohn’s disease(CICD) with the “simple endoscopic score for Crohn’s disease”(SES-CD), CDrelated surgery patients with the Rutgeerts score, and ulcerative colitis(UC) with the Mayo score. The efficacies of these evaluations to predict the endoscopic disease activity were assessed by Mann-Whitney test, χ~2 test, Spearman’s correlation, and multiple linear regression analysis.RESULTS The median FC levels in CD, UC, and IBS patients were 449.6(IQR, 137.9-1344.8), 497.9(IQR, 131.7-118.0), and 9.9(IQR, 0-49.7) μg/g, respectively(P < 0.001). For FC, CDAI or CAI, CRP, and ESR differed significantly between endoscopic active and remission in CICD and UC patients, but not in CD-related surgery patients. The SES-CD correlated closely with levels of FC(r = 0.802), followed by CDAI(r = 0.734), CRP(r = 0.658), and ESR(r = 0.557). The Mayo score also correlated significantly with FC(r = 0.837), CAI(r = 0.776), ESR(r = 0.644), and CRP(r = 0.634). For FC, a cut-off value of 250 μg/g indicated endoscopic active inflammation with accuracies of 87.5%, 60%, and 91.1%, respectively, for CICD, CD-related surgery, and UC patients. Moreover, clinical FC activity(CFA) calculated as 0.8 × FC + 4.6 × CDAI showed higher area under the curve(AUC) of 0.962 for CICD and CFA calculated as 0.2 × FC + 50 × CAI showed higher AUC(0.980) for UC patients than the FC. Also, the diagnostic accuracy of FC in identifying patients with mucosal inflammation in clinical remission was reflected by an AUC of 0.91 for CICD and 0.96 for UC patients. CONCLUSION FC is the most promising noninvasive evaluation for monitoring the endoscopic activity of CICD and UC. CFA might be more accurate for IBD activity evaluation.
AbstractList To optimize the efficacy of noninvasive evaluations in monitoring the endoscopic activity of inflammatory bowel disease (IBD). Fecal calprotectin (FC), clinical activity index (CDAI or CAI), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and procalcitonin (PCT) were measured for 136 IBD patients. Also, FC was measured in 25 irritable bowel syndrome (IBS) patients that served as controls. Then, endoscopic activity was determined by other two endoscopists for colonic or ileo-colonic Crohn's disease (CICD) with the "simple endoscopic score for Crohn's disease" (SES-CD), CD-related surgery patients with the Rutgeerts score, and ulcerative colitis (UC) with the Mayo score. The efficacies of these evaluations to predict the endoscopic disease activity were assessed by Mann-Whitney test, χ test, Spearman's correlation, and multiple linear regression analysis. The median FC levels in CD, UC, and IBS patients were 449.6 (IQR, 137.9-1344.8), 497.9 (IQR, 131.7-118.0), and 9.9 (IQR, 049.7) μg/g, respectively (P < 0.001). For FC, CDAI or CAI, CRP, and ESR differed significantly between endoscopic active and remission in CICD and UC patients, but not in CD-related surgery patients. The SES-CD correlated closely with levels of FC ( = 0.802), followed by CDAI ( = 0.734), CRP ( = 0.658), and ESR ( = 0.557). The Mayo score also correlated significantly with FC ( = 0.837), CAI (r = 0.776), ESR ( = 0.644), and CRP ( = 0.634). For FC, a cut-off value of 250 μg/g indicated endoscopic active inflammation with accuracies of 87.5%, 60%, and 91.1%, respectively, for CICD, CD-related surgery, and UC patients. Moreover, clinical FC activity (CFA) calculated as 0.8 × FC + 4.6 × CDAI showed higher area under the curve (AUC) of 0.962 for CICD and CFA calculated as 0.2 × FC + 50 × CAI showed higher AUC (0.980) for UC patients than the FC. Also, the diagnostic accuracy of FC in identifying patients with mucosal inflammation in clinical remission was reflected by an AUC of 0.91 for CICD and 0.96 for UC patients. FC is the most promising noninvasive evaluation for monitoring the endoscopic activity of CICD and UC. CFA might be more accurate for IBD activity evaluation.
AIMTo optimize the efficacy of noninvasive evaluations in monitoring the endoscopic activity of inflammatory bowel disease (IBD).METHODSFecal calprotectin (FC), clinical activity index (CDAI or CAI), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and procalcitonin (PCT) were measured for 136 IBD patients. Also, FC was measured in 25 irritable bowel syndrome (IBS) patients that served as controls. Then, endoscopic activity was determined by other two endoscopists for colonic or ileo-colonic Crohn's disease (CICD) with the "simple endoscopic score for Crohn's disease" (SES-CD), CD-related surgery patients with the Rutgeerts score, and ulcerative colitis (UC) with the Mayo score. The efficacies of these evaluations to predict the endoscopic disease activity were assessed by Mann-Whitney test, χ2 test, Spearman's correlation, and multiple linear regression analysis.RESULTSThe median FC levels in CD, UC, and IBS patients were 449.6 (IQR, 137.9-1344.8), 497.9 (IQR, 131.7-118.0), and 9.9 (IQR, 049.7) μg/g, respectively (P < 0.001). For FC, CDAI or CAI, CRP, and ESR differed significantly between endoscopic active and remission in CICD and UC patients, but not in CD-related surgery patients. The SES-CD correlated closely with levels of FC (r = 0.802), followed by CDAI (r = 0.734), CRP (r = 0.658), and ESR (r = 0.557). The Mayo score also correlated significantly with FC (r = 0.837), CAI (r = 0.776), ESR (r = 0.644), and CRP (r = 0.634). For FC, a cut-off value of 250 μg/g indicated endoscopic active inflammation with accuracies of 87.5%, 60%, and 91.1%, respectively, for CICD, CD-related surgery, and UC patients. Moreover, clinical FC activity (CFA) calculated as 0.8 × FC + 4.6 × CDAI showed higher area under the curve (AUC) of 0.962 for CICD and CFA calculated as 0.2 × FC + 50 × CAI showed higher AUC (0.980) for UC patients than the FC. Also, the diagnostic accuracy of FC in identifying patients with mucosal inflammation in clinical remission was reflected by an AUC of 0.91 for CICD and 0.96 for UC patients.CONCLUSIONFC is the most promising noninvasive evaluation for monitoring the endoscopic activity of CICD and UC. CFA might be more accurate for IBD activity evaluation.
AIM To optimize the efficacy of noninvasive evaluations in monitoring the endoscopic activity of inflammatory bowel disease(IBD).METHODS Fecal calprotectin(FC), clinical activity index(CDAI or CAI), C-reactive protein(CRP), erythrocyte sedimentation rate(ESR), and procalcitonin(PCT) were measured for 136 IBD patients. Also, FC was measured in 25 irritable bowel syndrome(IBS) patients that served as controls. Then, endoscopic activity was determined by other two endoscopists for colonic or ileo-colonic Crohn’s disease(CICD) with the “simple endoscopic score for Crohn’s disease”(SES-CD), CDrelated surgery patients with the Rutgeerts score, and ulcerative colitis(UC) with the Mayo score. The efficacies of these evaluations to predict the endoscopic disease activity were assessed by Mann-Whitney test, χ~2 test, Spearman’s correlation, and multiple linear regression analysis.RESULTS The median FC levels in CD, UC, and IBS patients were 449.6(IQR, 137.9-1344.8), 497.9(IQR, 131.7-118.0), and 9.9(IQR, 0-49.7) μg/g, respectively(P &lt; 0.001). For FC, CDAI or CAI, CRP, and ESR differed significantly between endoscopic active and remission in CICD and UC patients, but not in CD-related surgery patients. The SES-CD correlated closely with levels of FC(r = 0.802), followed by CDAI(r = 0.734), CRP(r = 0.658), and ESR(r = 0.557). The Mayo score also correlated significantly with FC(r = 0.837), CAI(r = 0.776), ESR(r = 0.644), and CRP(r = 0.634). For FC, a cut-off value of 250 μg/g indicated endoscopic active inflammation with accuracies of 87.5%, 60%, and 91.1%, respectively, for CICD, CD-related surgery, and UC patients. Moreover, clinical FC activity(CFA) calculated as 0.8 × FC + 4.6 × CDAI showed higher area under the curve(AUC) of 0.962 for CICD and CFA calculated as 0.2 × FC + 50 × CAI showed higher AUC(0.980) for UC patients than the FC. Also, the diagnostic accuracy of FC in identifying patients with mucosal inflammation in clinical remission was reflected by an AUC of 0.91 for CICD and 0.96 for UC patients. CONCLUSION FC is the most promising noninvasive evaluation for monitoring the endoscopic activity of CICD and UC. CFA might be more accurate for IBD activity evaluation.
Author Jin-Min Chen Tao Liu Shan Gao Xu-Dong Tong Fei-Hong Deng Biao Nie
AuthorAffiliation Department of Gastroenterology,Xiangyang Central Hospital,Hubei University of Arts and Science;Department of Gastroenterology,the Sixth Affiliated Hospital of Sun Yat-sen University;Guangdong Provincial Key Laboratory of Gastroenterology,Department of Gastroenterology,Nanfang Hospital,Southern Medical University;Department of Gastroenterology,the First Affiliated Hospital of Jinan University,Jinan University
Author_xml – sequence: 1
  givenname: Jin-Min
  surname: Chen
  fullname: Chen, Jin-Min
  organization: Department of Gastroenterology, Xiangyang Central Hospital, Hubei University of Arts and Science, Xiangyang 441021, Hubei Province, China
– sequence: 2
  givenname: Tao
  surname: Liu
  fullname: Liu, Tao
  organization: Department of Gastroenterology, the Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou 510665, Guangdong Province, China
– sequence: 3
  givenname: Shan
  surname: Gao
  fullname: Gao, Shan
  organization: Department of Gastroenterology, Xiangyang Central Hospital, Hubei University of Arts and Science, Xiangyang 441021, Hubei Province, China
– sequence: 4
  givenname: Xu-Dong
  surname: Tong
  fullname: Tong, Xu-Dong
  organization: Department of Gastroenterology, Xiangyang Central Hospital, Hubei University of Arts and Science, Xiangyang 441021, Hubei Province, China
– sequence: 5
  givenname: Fei-Hong
  surname: Deng
  fullname: Deng, Fei-Hong
  organization: Guangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong Province, China
– sequence: 6
  givenname: Biao
  surname: Nie
  fullname: Nie, Biao
  email: niebiao2@163.com
  organization: Department of Gastroenterology, the First Affiliated Hospital of Jinan University, Jinan University, Guangzhou 510630, Guangdong Province, China. niebiao2@163.com
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29290660$$D View this record in MEDLINE/PubMed
BookMark eNpVkUFv1DAQhS1URLcLd07IRy5ZxnacxByQ0KrQSpW4wNmaJPauq8Texkmq_HscuqzAF3s8b549892QKx-8IeQ9g50o8-rT8-NhN3Oxc3mxq7iQr8iGc6YyXuVwRTYMoMyU4OU1uYnxEYALIfkbcs0VV1AUsCHx1lrXYLPQYGlyd37G6GZDzYzdhKMLPlLnaZ9SYxicP6TIdtj3mMKF1uHZdLR10WA0FJvRzW5cPlOkpyHEk1kvDI3j1C6rzf7oPL4lry120bw771vy69vtz_1d9vDj-_3-60PWSCjGTLQSG14bVRvGoagBcistly1wLqC2rcWaCdZUDIWpTdlKKYq6VMhKCTwvxZZ8efE9TXVv2sb4ccBOnwbX47DogE7_n_HuqA9h1rIUSglIBh_PBkN4mkwcde9iY7oOvQlT1ExVgsuCJfGWwIu0SW3HwdjLMwz0ykonVjqx0omVXlmlkg__fu9S8BdOEoiz5zH4w1Oa_UWjoFqXkpBXuZJScpn_OXHxG31lpd4
CitedBy_id crossref_primary_10_1016_j_mri_2024_06_001
crossref_primary_10_1080_07853890_2022_2082518
crossref_primary_10_14309_ajg_0000000000000596
crossref_primary_10_1177_17562848231167283
crossref_primary_10_1186_s12876_023_02769_5
crossref_primary_10_13105_wjma_v8_i2_163
crossref_primary_10_3748_wjg_v30_i1_50
crossref_primary_10_1016_j_cgh_2021_03_048
crossref_primary_10_12998_wjcc_v9_i2_334
crossref_primary_10_3390_jcm11206086
crossref_primary_10_1053_j_gastro_2020_12_031
crossref_primary_10_1016_j_cgh_2018_12_021
crossref_primary_10_1080_1744666X_2019_1593140
crossref_primary_10_1097_MEG_0000000000001731
crossref_primary_10_3390_biomedicines8070193
crossref_primary_10_1371_journal_pone_0223893
crossref_primary_10_15406_ghoa_2022_13_00494
crossref_primary_10_3748_wjg_v24_i33_3681
crossref_primary_10_3390_biomedicines11051408
crossref_primary_10_1016_j_heliyon_2023_e23439
crossref_primary_10_14309_ctg_0000000000000134
crossref_primary_10_1155_2018_5090849
crossref_primary_10_3390_jcm10102203
crossref_primary_10_1093_ecco_jcc_jjab182
crossref_primary_10_1111_cts_13575
crossref_primary_10_3164_jcbn_19_90
crossref_primary_10_3390_diagnostics10060367
crossref_primary_10_1371_journal_pone_0255012
crossref_primary_10_1080_00325481_2018_1503919
crossref_primary_10_1080_17474124_2023_2296564
crossref_primary_10_1097_MPG_0000000000002262
crossref_primary_10_1155_2019_3108025
Cites_doi 10.1016/j.crohns.2011.09.008
10.1002/ibd.20312
10.1111/apt.12335
10.1038/nrgastro.2014.154
10.1053/j.gastro.2013.04.007
10.1097/00042737-200208000-00005
10.1016/0016-5085(90)90613-6
10.1186/1756-0500-2-221
10.1016/S0016-5107(04)01878-4
10.3748/wjg.v19.i45.8335
10.1038/ajg.2014.45
10.1097/MCG.0000000000000774
10.1097/MD.0000000000003477
10.3109/00365521.2012.660542
10.1097/MIB.0b013e3182810066
10.3109/00365521.2013.772230
10.1136/bmj.298.6666.82
10.1002/ibd.20986
10.15403/jgld.2014.1121.233.thv
10.1002/ibd.21838
10.1111/j.1572-0241.2007.01561.x
10.4318/tjg.2012.0421
10.1016/S0016-5085(76)80163-1
10.1097/MIB.0000000000001050
10.1136/gut.27.7.809
10.1002/bjs.6593
10.1111/j.1365-2036.2008.03835.x
10.1016/j.crohns.2013.09.016
10.1038/nature06005
10.1136/gut.2005.069476
10.1111/j.1365-2036.2010.04459.x
10.1016/j.cgh.2010.01.016
10.1111/jgh.12164
10.1002/ibd.21925
10.1007/s10350-007-0225-6
10.1007/s10620-016-4397-6
10.1097/MIB.0b013e31828a6551
10.1056/NEJM198712243172603
10.1016/j.crohns.2013.12.015
10.1038/ajg.2009.545
10.1177/2050640613501818
10.1053/j.gastro.2007.05.051
10.1097/MIB.0000000000000139
ContentType Journal Article
Copyright The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. 2017
Copyright_xml – notice: The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. 2017
DBID 2RA
92L
CQIGP
~WA
NPM
AAYXX
CITATION
7X8
5PM
DOI 10.3748/wjg.v23.i46.8235
DatabaseName 维普_期刊
中文科技期刊数据库-CALIS站点
维普中文期刊数据库
中文科技期刊数据库- 镜像站点
PubMed
CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle PubMed
CrossRef
MEDLINE - Academic
DatabaseTitleList PubMed
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
EISSN 2219-2840
EndPage 8247
ExternalDocumentID 10_3748_wjg_v23_i46_8235
29290660
90888889504849555254484952
Genre Journal Article
GroupedDBID ---
123
29R
2B.
2C~
2RA
2WC
36B
53G
5VR
8WL
92F
92I
92L
93N
93R
AAKDD
ACGFO
AENEX
AFUIB
ALMA_UNASSIGNED_HOLDINGS
CCEZO
CHBEP
CIEJG
CQIGP
CS3
CW9
DIK
DU5
E3Z
EBS
EJD
EMB
F5P
FA0
FRP
GX1
HYE
M~E
OK1
P2P
RNS
RPM
SV3
TCJ
TGQ
TR2
WFFXF
XSB
~WA
NPM
AAYXX
CITATION
7X8
5PM
ID FETCH-LOGICAL-c506t-3d5ac2be9be1206b004f5f25d02230bfdfab131c81a3ebe7d5536b79a17502473
IEDL.DBID RPM
ISSN 1007-9327
IngestDate Fri Sep 01 02:33:39 EDT 2023
Fri Apr 12 08:55:27 EDT 2024
Fri Aug 23 00:26:54 EDT 2024
Sat Sep 28 08:50:01 EDT 2024
Wed Feb 14 10:07:48 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed false
IsScholarly true
Issue 46
Keywords Fecal calprotectin
Inflammatory bowel disease
Disease activity
Crohn’s disease
Ulcerative colitis
Language English
License This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c506t-3d5ac2be9be1206b004f5f25d02230bfdfab131c81a3ebe7d5536b79a17502473
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Correspondence to: Biao Nie, MD, PhD, Professor, Associate Chief Physician, Department of Gastroenterology, the First Affiliated Hospital of Jinan University, Jinan University, No. 614, West Huangpu Avenue, Guangzhou 510630, Guangdong Province, China. niebiao2@163.com
Telephone: +86-15101503392 Fax: +86-20-38688025
Author contributions: Chen JM and Nie B designed the study and wrote the manuscript; Deng FH collected fecal and blood samples and completed patient case report; Liu T and Nie B performed all endoscopies and completed the endoscopic scoring sheet; Tong XD quantified fecal calprotectin; Gao S performed data analysis; all authors read and approved the final manuscript.
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739930/
PMID 29290660
PQID 1983256199
PQPubID 23479
PageCount 13
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_5739930
proquest_miscellaneous_1983256199
crossref_primary_10_3748_wjg_v23_i46_8235
pubmed_primary_29290660
chongqing_primary_90888889504849555254484952
PublicationCentury 2000
PublicationDate 2017-12-14
PublicationDateYYYYMMDD 2017-12-14
PublicationDate_xml – month: 12
  year: 2017
  text: 2017-12-14
  day: 14
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle World journal of gastroenterology : WJG
PublicationTitleAlternate World Journal of Gastroenterology
PublicationYear 2017
Publisher Baishideng Publishing Group Inc
Publisher_xml – name: Baishideng Publishing Group Inc
References 23161295 - Turk J Gastroenterol. 2012;23(5):509-14
23669403 - Inflamm Bowel Dis. 2013 Aug;19(9):1839-45
16474109 - Gut. 2006 Mar;55(3):426-31
22069022 - Inflamm Bowel Dis. 2012 Sep;18(9):1634-40
3317057 - N Engl J Med. 1987 Dec 24;317(26):1625-9
18076736 - Am J Gastroenterol. 2008 Jan;103(1):154-61
2563951 - BMJ. 1989 Jan 14;298(6666):82-6
22398068 - J Crohns Colitis. 2012 May;6(4):412-8
19874614 - BMC Res Notes. 2009 Oct 29;2:221
3732890 - Gut. 1986 Jul;27(7):809-13
23432198 - J Gastroenterol Hepatol. 2013 Jul;28(7):1148-53
28426458 - Inflamm Bowel Dis. 2017 May;23 (5):791-797
25201042 - Nat Rev Gastroenterol Hepatol. 2014 Oct;11(10):583-4
24184171 - J Crohns Colitis. 2013 Dec;7(12):982-1018
24917985 - United European Gastroenterol J. 2013 Oct;1(5):368-74
23328771 - Inflamm Bowel Dis. 2013 Feb;19(2):332-41
23668698 - Aliment Pharmacol Ther. 2013 Jul;38(1):44-51
20139033 - Clin Gastroenterol Hepatol. 2010 Jul;8(7):591-9.e1; quiz e78-9
24418661 - J Crohns Colitis. 2014 Aug;8(8):789-95
23583432 - Gastroenterology. 2013 Jul;145(1):158-165.e2
15472670 - Gastrointest Endosc. 2004 Oct;60(4):505-12
19384912 - Br J Surg. 2009 Jun;96(6):663-74
19755969 - Am J Gastroenterol. 2010 Jan;105(1):162-9
17473939 - Dis Colon Rectum. 2007 Jun;50(6):861-9
21830282 - Inflamm Bowel Dis. 2012 Jun;18(6):1006-10
19462421 - Inflamm Bowel Dis. 2009 Dec;15(12):1851-8
27984399 - J Clin Gastroenterol. 2016 Dec 14;:null
22356594 - Scand J Gastroenterol. 2012 May;47(5):528-37
18022866 - Inflamm Bowel Dis. 2008 Jan;14(1):40-6
24642581 - Am J Gastroenterol. 2014 May;109(5):705-14
1248701 - Gastroenterology. 1976 Mar;70(3):439-44
24363525 - World J Gastroenterol. 2013 Dec 7;19(45):8335-41
23477356 - Scand J Gastroenterol. 2013 May;48(5):543-51
2394349 - Gastroenterology. 1990 Oct;99(4):956-63
27933473 - Dig Dis Sci. 2017 Feb;62(2):465-472
21039675 - Aliment Pharmacol Ther. 2010 Nov;32(9):1135-44
25267955 - J Gastrointestin Liver Dis. 2014 Sep;23(3):273-8
17681162 - Gastroenterology. 2007 Aug;133(2):412-22
18752630 - Aliment Pharmacol Ther. 2008 Nov 15;28(10):1221-9
27100452 - Medicine (Baltimore). 2016 Apr;95(16):e3477
25137415 - Inflamm Bowel Dis. 2014 Oct;20(10):1747-53
17653185 - Nature. 2007 Jul 26;448(7152):427-34
12172403 - Eur J Gastroenterol Hepatol. 2002 Aug;14(8):841-5
ref13
ref35
ref12
ref34
ref15
ref37
ref14
ref36
ref31
ref30
ref11
ref33
ref10
ref32
ref2
ref1
ref17
ref39
ref16
ref38
ref19
ref18
ref24
ref23
ref26
ref25
ref20
ref42
ref41
ref22
ref21
ref43
ref28
ref27
ref29
ref8
ref7
ref9
ref4
ref3
ref6
ref5
ref40
References_xml – ident: ref6
  doi: 10.1016/j.crohns.2011.09.008
– ident: ref30
  doi: 10.1002/ibd.20312
– ident: ref8
  doi: 10.1111/apt.12335
– ident: ref27
  doi: 10.1038/nrgastro.2014.154
– ident: ref3
  doi: 10.1053/j.gastro.2013.04.007
– ident: ref26
  doi: 10.1097/00042737-200208000-00005
– ident: ref18
  doi: 10.1016/0016-5085(90)90613-6
– ident: ref31
  doi: 10.1186/1756-0500-2-221
– ident: ref16
  doi: 10.1016/S0016-5107(04)01878-4
– ident: ref25
  doi: 10.3748/wjg.v19.i45.8335
– ident: ref28
  doi: 10.1038/ajg.2014.45
– ident: ref41
  doi: 10.1097/MCG.0000000000000774
– ident: ref14
  doi: 10.1097/MD.0000000000003477
– ident: ref29
  doi: 10.3109/00365521.2012.660542
– ident: ref34
  doi: 10.1097/MIB.0b013e3182810066
– ident: ref9
  doi: 10.3109/00365521.2013.772230
– ident: ref21
  doi: 10.1136/bmj.298.6666.82
– ident: ref33
  doi: 10.1002/ibd.20986
– ident: ref43
  doi: 10.15403/jgld.2014.1121.233.thv
– ident: ref11
  doi: 10.1002/ibd.21838
– ident: ref2
  doi: 10.1111/j.1572-0241.2007.01561.x
– ident: ref35
  doi: 10.4318/tjg.2012.0421
– ident: ref20
  doi: 10.1016/S0016-5085(76)80163-1
– ident: ref42
  doi: 10.1097/MIB.0000000000001050
– ident: ref23
  doi: 10.1136/gut.27.7.809
– ident: ref37
  doi: 10.1002/bjs.6593
– ident: ref32
  doi: 10.1111/j.1365-2036.2008.03835.x
– ident: ref12
  doi: 10.1016/j.crohns.2013.09.016
– ident: ref1
  doi: 10.1038/nature06005
– ident: ref22
  doi: 10.1136/gut.2005.069476
– ident: ref24
  doi: 10.1111/j.1365-2036.2010.04459.x
– ident: ref40
  doi: 10.1016/j.cgh.2010.01.016
– ident: ref5
  doi: 10.1111/jgh.12164
– ident: ref7
  doi: 10.1002/ibd.21925
– ident: ref36
  doi: 10.1007/s10350-007-0225-6
– ident: ref15
  doi: 10.1007/s10620-016-4397-6
– ident: ref4
  doi: 10.1097/MIB.0b013e31828a6551
– ident: ref19
  doi: 10.1056/NEJM198712243172603
– ident: ref38
  doi: 10.1016/j.crohns.2013.12.015
– ident: ref17
  doi: 10.1038/ajg.2009.545
– ident: ref39
  doi: 10.1177/2050640613501818
– ident: ref10
  doi: 10.1053/j.gastro.2007.05.051
– ident: ref13
  doi: 10.1097/MIB.0000000000000139
SSID ssj0023352
Score 2.4458706
Snippet AIM To optimize the efficacy of noninvasive evaluations in monitoring the endoscopic activity of inflammatory bowel disease(IBD).METHODS Fecal...
To optimize the efficacy of noninvasive evaluations in monitoring the endoscopic activity of inflammatory bowel disease (IBD). Fecal calprotectin (FC),...
AIMTo optimize the efficacy of noninvasive evaluations in monitoring the endoscopic activity of inflammatory bowel disease (IBD).METHODSFecal calprotectin...
SourceID pubmedcentral
proquest
crossref
pubmed
chongqing
SourceType Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 8235
SubjectTerms Prospective Study
Title Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: a prospective study in China
URI http://lib.cqvip.com/qk/84123X/201746/90888889504849555254484952.html
https://www.ncbi.nlm.nih.gov/pubmed/29290660
https://search.proquest.com/docview/1983256199
https://pubmed.ncbi.nlm.nih.gov/PMC5739930
Volume 23
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3BTtwwEB0Bl3KpqCgQoJUr9VKpycZ2HK-5IQRClah6KBK3yPbadCs2C-wC4u-Z8SbbLr01p0SxI8dv7Bl7Zp4BPkcXFKr5SJFqKq-GPOYmVDIPJiivvZU2eXQvvtfnl9W3K3W1BqrPhUlB-96Ni_ZmUrTjXym28nbiB32c2ODHxYnSpFbLwTqsayn7JXq3yqIkouTiLHWOxole-CaJZWXw9Pu6eBSyGFd1MRSSTq0RhvjOiaDyDU437fUdKoxVFfWP3fk6fPIvfXS2BW87Q5IdLxr8DtZCuw2zU2KEsP6ZTSNraaf10VJ8OvtD6j1j45ZN0kimLT18iigUk-RsZ276FG5Y57RhlPNAR0scsWOG7euTMlmipKXPpMO338Pl2enPk_O8O1Yh96qs57kcKeuFC8YFLsqaxm1UUagRqnNZujiK1nHJ_ZBbiRDrkVKydtpYtDRQo2u5Axv4B2EPWKisJaMtameqGqsMubc4bUnsVu55mcHXZa82twv6jIYiq_AyCicPXJ4pRSxpdCcy-NJ3_LI0LlIIuwaxaxC7BrFrCLsMPvXINDgiyM1h2zB9mDXc4CyFZqExGewukFp-rYc7A72C4bIAsW2vvkEhTKzbndDt_3fNA9gUZBNwkfPqEDbm9w_hA1o0c_cxSfAL4u32Uw
link.rule.ids 230,315,733,786,790,891,27955,27956,53825,53827
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VcigXHuKV8jISFySSje04WXOrqlYLdCsOLeotsr12u9DNtuxuK_j1zDibhS0nyClR7EjWfJ75nBl_BngTrFcY5gNVqqm06POQal_I1GuvXOWMNDGjOzwsB8fFxxN1sgGq2wsTi_adHWfN-SRrxmextvJi4npdnVjv83BXVRRW894tuI3zVahukb5cZ9E2opjkzKsU6UnVZidJZ6V3_fU0uxIyGxdl1heSzq0RmhTPSaJyCx1Oc3qJIWM9SP3FPG8WUP4RkfbvwZduLG0hyrdsMbeZ-3lD5vGfB3sf7i45KttpXz-ADd88hNkeiU0Y94NNA2voJ-6VodJ39lsvfMbGDZtEJ0F_C_EpIN4mMY_P7PTan7NlPojRdgo6teI922E4gG6_J4tqt_SZeK73Izje3zvaHaTLExtSp_JynsqRMk5Yr63nIi_JJQQVhBohU5C5DaNgLJfc9bmRiJ5qpJQsbaUNkhgkC5V8DJs4Av8UmC-MIT4YKquLErv0uTPoESXaizueJ_BuZa76olXmqKloCy-t0C_hyk8pEmCjO5HA286iq9a4_iFQ1AiKGkFRIyhqAkUCrzuT1zjZKINiGj9dzGqu0QEi49Q6gSctBFZf63CUQLUGjlUDEvJef4Mmj4LeSxNv_3fPV7A1OBoe1AcfDj89gzuCqAcXKS-ew-b8-8K_QOI0ty_jNPkF_BEYXA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagSMCFh4ASnkbigkQetuN4za0qXZVHqx6oVHGJbMcuS7vZLbvbCn49M85m6ZZbc9ponUjWfJ75nBl_Q8jbYL2EMB-wUk2m5YCFVPtSpF576ZQzwsSM7t5-tXtYfj6SR5dafcWifWdHWXs6ztrRj1hbOR27vK8Tyw_2tqXCsFrk0ybkN8ktWLNc9Rv15V4LjxLFRGehUqAoqstQotZKfvHzODvnIhuVVTbgAnvXcI2q5yhTeQecTnt8BmFjPVD9xz6vFlFeikrD--R7P5-uGOUkW8xt5v5ckXq81oQfkHtLrkq3uiEPyQ3fPiKzHRSdMO43nQTa4sfcc4Ml8PSfbviMjlo6js4CvxrCXQDcjWM-n9rJhT-ly7wQxWMV2L3iA92iMIn-3CeNqrf4mtjf-zE5HO58295Nl50bUieLap6KRhrHrdfWM15U6BqCDFw2wBhEYUMTjGWCuQEzAlCkGilFZZU2QGaANCjxhGzADPxTQn1pDPLCoKwuK3hkwJwBzyjAZsyxIiHvVyarp51CR43FW3BpCf4JdoBSohAb_uIJeddbdTUa9kEIjBqAUQMwagBGjcBIyJve7DUsOsykmNZPFrOaaXCEwDy1TshmB4PV23osJUStAWQ1AAW91_8Bs0dh76WZn137ydfk9sHHYf310_6X5-QuRwbCeMrKF2Rj_mvhXwJ_mttXcaX8Bb5wGtw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Efficacy+of+noninvasive+evaluations+in+monitoring+inflammatory+bowel+disease+activity%3A+A+prospective+study+in+China&rft.jtitle=World+journal+of+gastroenterology+%3A+WJG&rft.au=Chen%2C+Jin-Min&rft.au=Liu%2C+Tao&rft.au=Gao%2C+Shan&rft.au=Tong%2C+Xu-Dong&rft.date=2017-12-14&rft.issn=1007-9327&rft.volume=23&rft.issue=46&rft.spage=8235&rft.epage=8247&rft_id=info:doi/10.3748%2Fwjg.v23.i46.8235&rft.externalDBID=n%2Fa&rft.externalDocID=10_3748_wjg_v23_i46_8235
thumbnail_s http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F84123X%2F84123X.jpg